Sushanth Sreenivasan

Dr. Sushanth Sreenivasan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SSSushanth Sreenivasan
Sushanth Sreenivasan
RJRahim A. Jiwani
Rahim A. Jiwani
RWRichard White
Richard White
VBV B
V B
RMRyan Moll
Ryan Moll
LGLarisa Greenberg
Larisa Greenberg
Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, and RET receptors. These have facilitated the development of targeted therapies, including TRK inhibitors, HER2-directed agents, and androgen receptor modulators, as well as emerging combinations of immunotherapy and chemotherapy. Despite these advancements, challenges such as resistance mechanisms and limited therapeutic efficacy persist. Overall response rates remain relatively low across most systemic therapies, reflecting a persistent unmet clinical need. This review discusses the current landscape of treatment options and explores promising clinical trials and future directions to enhance outcomes for patients with SGCs.

1 April 2023 in Journal of Hematology
Verified
Journal Article
Open access
SSSushanth Sreenivasan
Sushanth Sreenivasan
RSRisha Solanki
Risha Solanki
PKPragnan Kancharla
Pragnan Kancharla
CKCyrus Khan
Cyrus Khan
YSYazan Samhouri
Yazan Samhouri
Primary central nervous system lymphoma (PCNSL) is an aggressive form of extranodal non-Hodgkin lymphoma that arises in the brain parenchyma, eyes, meninges, or spinal cord in the absence of systemic disease. Primary dural lymphoma (PDL), in contrast, arises from the dura mater of the brain. PDL is usually a low-grade B-cell marginal zone lymphoma (MZL), whereas other types of PCNSL are usually high-grade large B-cell lymphoma. This specific pathological subtype has important therapeutic and prognostic implications, making PDL a distinct subtype of PCNSL. Herein, we report a case of PDL in an African American patient, in her late thirties, who presented to our emergency room with chronic headaches. An emergent magnetic resonance imaging (MRI) of the brain showed a dural-based homogeneously enhancing extra-axial mass along the left hemisphere, which was contained within the anterior and parietal dural mater. A surgical specimen was collected after an emergency debulking procedure. The flow cytometry, done on the surgical specimen obtained, was positive for CD19+, CD20+, and CD22+, but negative for CD5- and CD10-. These findings were consistent with a clonal B-lymphoproliferative disorder. The surgical pathology specimen immunohistochemistry was positive for CD20+ and CD45+, but negative for Bcl-6Cyclin D1- and CD56-. The Ki67 was 10-20%. These findings were consistent with extranodal MZL. Given the location and pathology, the patient was diagnosed with PDL. Due to MZL’s indolent nature, location outside the blood-brain barrier, and known efficacy to bendamustine-rituximab (BR), we decided to treat our patient with BR. She completed six cycles without major complications, and her post-therapy brain MRI showed complete remission (CR). Our case adds to the sparse literature about PDL and highlights the efficacy of BR systemic chemotherapy on MZLs.

30 July 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAKSHIT CHITKARA
AKSHIT CHITKARA
SSSushanth Sreenivasan
Sushanth Sreenivasan
YYYue Yin
Yue Yin
MRMaitreyee Rai
Maitreyee Rai
SSSanthosh Sadashiv
Santhosh Sadashiv
Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review, we study the risk of venous thromboembolism (VTE) associated with CAR-T therapy. We searched the National Institutes of Health library, Cochrane Library Databases, ClinicalTrials.gov database, and medical literature search engines PubMed and Google Scholar for Phase 2 and Phase 3 drug-efficacy and safety trials to determine the aggregate incidence and risk of VTE treated with CAR-T. Of 1127 search results, nine studies were identified and included in our meta-analysis. Of the 1017 patients who received therapy, 805 patients (79.15%) experienced some degree of CRS, and 122 patients (11.9%) experienced severe CRS (higher than grade 3). Only three out of one thousand and seventeen patients were reported to have experienced venous thromboembolism. Our study did not find a statistically significant association between increased VTE incidence (OR = 0.0005, 95% CI [0.0001, 0.0017]) and CRS/ICANS (p < 0.0001). There was a 0.0050 (95% confidence interval [0.0019, 0.0132]) relative risk for VTE. In our study, we did not find a statistically significantly increased risk of developing VTE despite CRS and underlying malignancy, which have been associated with increased risk of VTE.

1 October 2024 in Journal of Hematology
Verified
Journal Article
Open access
PDF file
LLLane Lerner
Lane Lerner
SSSushanth Sreenivasan
Sushanth Sreenivasan
CPChelsea Peterson
Chelsea Peterson
MRMaitreyee Rai
Maitreyee Rai
PKPragnan Kancharla
Pragnan Kancharla
YSYazan Samhouri
Yazan Samhouri
Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood Associated With t(1;22)(p22;q11.2) Mutation

22 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DDDipanjan Debnath
Dipanjan Debnath
HAHassan Abdulahi
Hassan Abdulahi
AAAbigail Arrigo
Abigail Arrigo
MDMadhurima Debnath
Madhurima Debnath
KDKriti Dhamija
Kriti Dhamija
GFGene Finley
Gene Finley
Concurrent chemoradiation (cCRT) is standard for unresectable, locally advanced non–small cell lung cancer (NSCLC), but the preferred concurrent chemotherapy backbone is uncertain. Cisplatin–etoposide (EP) and weekly carboplatin–paclitaxel (PC) are commonly used. Background/Objectives: Retrospective single-institution cohort of adults with histologically confirmed, inoperable AJCC stage II–III NSCLC treated 2015–2023 with definitive thoracic radiation plus concurrent EP or PC. Methods: We collected clinical characteristics, treatment completion, best radiographic response, adverse events (AEs), progression, and death. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints were overall response rate (ORR) and AEs. Kaplan–Meier survival estimates were generated and compared using log-rank testing; hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: Among 177 patients (EP, n = 43; PC, n = 134), stage III disease comprised 91% in the EP cohort and 90% in the PC cohort. ORR favored EP (63% vs 52%), and primary progressive disease as best response was less frequent with EP (7% vs 21%, p = 0.04). Median PFS was 48.07 vs 14.93 months (HR 0.65, 95% CI 0.43–0.90; p = 0.05). Median OS numerically favored EP (76.97 vs 34.60 months; HR 0.70, 95% CI 0.44–1.12; p = 0.17). Any-grade AEs occurred at similar rates (34.9% vs 34.3%), whereas grade 3–4 AEs were more frequent with EP (25.6% vs 9.7%; p = 0.02). Conclusion: EP-based cCRT was associated with longer PFS and higher grade 3–4 toxicity than PC; findings support individualized selection and need validation, especially in the immunotherapy era.

23 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
SSSushanth Sreenivasan
Sushanth Sreenivasan
SRSolanki Risha
Solanki Risha
PKPragnan Kancharla
Pragnan Kancharla
CKCyrus Khan
Cyrus Khan
YSYazan Samhouri
Yazan Samhouri
Primary CNS lymphoma (PCNSL) is an aggressive form of extranodal non-Hodgkin lymphoma that arises in the brain parenchyma, eyes, meninges, or spinal cord in the absence of systemic disease. Primary dural lymphoma (PDL) arises from the dura mater of the brain. It differs biologically from other CNS lymphomas. It is usually a low-grade B-cell marginal zone lymphoma (MZL), whereas other types of PCNSL are usually high-grade large B-cell lymphoma. This specific pathological subtype has important therapeutic and prognostic implications, making PDL a distinct subtype of PCNSL. Herein, we report a case of PDL in an African American patient who presented with chronic headaches. MRI of the brain showed a dural-based homogeneously enhancing extra-axial mass along the left hemisphere and was contained within the anterior and parietal dural matter. The malignant cells stained diffusely positive for CD19, CD20, and CD22 but negative for CD5, CD10, Cyclin D1, and CD56. Ki67 was 10–20%, consistent with extranodal marginal zone lymphoma. Given the location and pathology, the patient was diagnosed with PDL. She was started on treatment with bendamustine and rituximab. Due to Marginal Zone Lymphoma’s indolent nature, location outside the blood brain barrier, and known efficacy of bendamustine-rituximab, we decided to treat our patient with Bendamustine-Rituxumab. She completed six cycles, and post-therapy MRI brain showed complete remission. Our case adds to the sparse literature about primary dural lymphoma.